share_log

Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Drop in Short Interest

Financial News Live ·  Jan 21, 2023 11:11

Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Rating) saw a large drop in short interest in December. As of December 30th, there was short interest totalling 288,200 shares, a drop of 31.9% from the December 15th total of 423,100 shares. Based on an average trading volume of 428,700 shares, the days-to-cover ratio is currently 0.7 days.

Plus Therapeutics Trading Down 2.3 %

PSTV traded down $0.01 during midday trading on Friday, hitting $0.43. 206,454 shares of the company were exchanged, compared to its average volume of 493,002. The firm has a market capitalization of $14.45 million, a P/E ratio of -0.48 and a beta of 0.42. Plus Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.20. The firm's 50 day moving average price is $0.38 and its 200-day moving average price is $0.50. The company has a quick ratio of 2.81, a current ratio of 2.81 and a debt-to-equity ratio of 0.36.

Get Plus Therapeutics alerts:

Plus Therapeutics (NASDAQ:PSTV – Get Rating) last announced its earnings results on Thursday, October 20th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. The company had revenue of $0.07 million for the quarter. As a group, equities analysts forecast that Plus Therapeutics will post -0.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PSTV. Otter Creek Advisors LLC increased its position in Plus Therapeutics by 293.5% in the 2nd quarter. Otter Creek Advisors LLC now owns 330,168 shares of the company's stock valued at $178,000 after buying an additional 246,267 shares in the last quarter. Vanguard Group Inc. increased its position in Plus Therapeutics by 20.0% in the 1st quarter. Vanguard Group Inc. now owns 855,264 shares of the company's stock valued at $855,000 after buying an additional 142,417 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Plus Therapeutics by 50.1% during the 2nd quarter. Renaissance Technologies LLC now owns 101,093 shares of the company's stock worth $55,000 after purchasing an additional 33,735 shares in the last quarter. 10.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Jonestrading assumed coverage on Plus Therapeutics in a report on Thursday, October 6th. They set a "buy" rating and a $5.00 target price on the stock.

Plus Therapeutics Company Profile

(Get Rating)

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Plus Therapeutics (PSTV)
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment